Dr. Zhangming Niu of MindRank AI Named to 'U45 Influential Youth' at 2024 China Biopharma Innovation Awards

The Innovation风云榜 of China's Biomedical Industry Chain, initiated by the Joint Body for Innovation and Transformation of China's Biomedical Industry Chain, always adheres to the purpose of "setting industry benchmarks, stimulating innovation potential, and fostering an innovative environment." It is committed to exploring the veins of industry transformation in depth and promoting the development of China's new pharmaceuticals industry. Having been consecutively awarded for five sessions, it has become a benchmark award in the field of innovation and transformation within the biomedical industry.

This year, the "U45 Influential Youth" award has been established for the first time in the风云榜 (Fengyun Ranking), targeting candidates from the成员单位 (member units) and partner organizations of the China Biomedical Industry Innovation and Transformation Alliance (CBIITA). Through authoritative data analysis across multiple dimensions and verification from various perspectives, 45 individuals under the age of 45 have been selected to be honored.Advanced scientific and technological workers who have made outstanding contributions in scientific and technological innovation and industrial innovation, and young scientists with profound influence in the field of biomedicine for industry-university-research-application.

As the founder and CEO of "MindRank," Niu Zhangming has over 10 years of R&D and management experience in European and American listed companies, and 7 years of AI pharmaceutical industry experience. He once served as a director/CTO of a German main-board listed AI medical company. Niu Zhangming has long been focused on research related to AI-accelerated precision drug development, and has published dozens of papers in international top-tier journals such as Nature and Cell series sub-journals. He also led "MindRank."Molecule Pro™、Molecule Dance™、PharmKG™And a series of internationally leading AI pharmaceutical platform development and innovative drug pipeline research and development.

Zhangming Niu and the "MindRank" team are committed to deeply applying cutting-edge AI technology in the pharmaceutical field, delivering better drugs to patients more quickly. Currently, the company has partnered with globally leadingMultinational pharmaceutical company Merck, University of Cambridge, and Imperial College LondonMindRank has established in-depth technology R&D collaborations with top-tier research institutions and is jointly accelerating the development of innovative drugs with multiple listed pharmaceutical companies in China. The company's first self-developed GLP-1RA small molecule oral drug, MDR-001, is proceeding smoothly.Phase IIb Clinical Study,Multiple projects in the fields of oncology and metabolic diseases have reached the IND-Enabling stage. The team continues to empower new drug research and development with AI technology, driving the effective implementation of "Technology for Good."

Original link:

CBIITA Ranking Releases "U45 Influential Youth" List for the First Time!

The China Biomedical Industry Innovation and Transformation Consortium, abbreviated as CBIITA Consortium, is guided by the China Association for Promoting Cooperation in Industry, Academia, and Research. It was jointly initiated by authoritative national industry associations such as the China Chemical Pharmaceutical Industry Association, the Chinese Pharmacological Society, the Chinese Toxicology Society, the National Key Laboratory Alliance of Pharmacy, strategic national scientific and technological forces like the Sino-European Life Science Alliance, and the Editorial Board of "Progress in Pharmaceutical Sciences." It serves as an ecological empowerment platform for China's biomedical industry chain. Academician Chen Kai-Xian and Deng Zi-Xin of the Chinese Academy of Sciences serve as co-chairmen.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby helping more lives regain health.

MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018-2020" by the authoritative European and American institution, Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Companies list as one of "China's most socially impactful startups."

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai